Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eli Lilly and Company
Scientific Title
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer